Ultragenyx Pharmaceutical, Inc. Aktie News

Preliminary 2025 total revenue of $672 million to $674 million, exceeding top end of guidance  Preliminary cash and investments of approximately $735 million as of December 31, 2025 Anticipated 2026 catalysts include two potential approvals and pivotal Phase 3 data from the GTX-102 Phase 3 Aspire study for Angelman syndrome

If approved, DTX401 will be the first therapy approved to treat the underlying cause of GSDIa If approved, DTX401 will be the first therapy approved to treat the underlying cause of GSDIa

A Wells Fargo analyst cut his price target on Ultragenyx stock, though it still implies significant upside from yesterday's closing price. Ultragenyx reported yesterday that two Phase 3 studies failed to achieve primary endpoints for setrusumab.

LOS ANGELES, Dec. 30, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Ultragenyx Pharmaceutical, Inc. (“Ultragenyx" or the "Company") (NASDAQ: RARE) investors that the firm has initiated an investigation into possible securities fraud, and may file a class action on behalf of investors.

Ultragenyx Pharmaceuticals reported Phase 3 results for setrusumab, a potential treatment for osteogenesis imperfecta. Several firms have reduced their price targets on Ultragenyx stock.

Shares of both Ultragenyx and Mereo BioPharma were seeing record selloffs after disappointing trial results for setrusumab.

Ultragenyx Pharmaceutical said on Monday that its experimental drug for a type of genetic bone disease did not meet the main goal in late-stage studies.

Neither study achieved its primary endpoint of reduction in annualized clinical fracture rate compared to placebo (Orbit) or bisphosphonates (Cosmic)